Abcam plc (Abcam), a in vitro diagnostics company, has appointed Michael Redmond as the company's non-executive deputy chairman. Redmond has substantial, international experience in the pharmaceutical industry gained in both executive and non-executive capacities at businesses ranging from multinational organisations to start-up companies. Redmond is currently non-executive chairman of Dechra Pharmaceuticals plc.
And his recent chairmanships include Synexus Clinical Research plc, Arakis Ltd and Mircroscience Ltd.
His executive career began at Glaxo Group plc in 1967 and was followed, from 1975 to 1990, by senior positions in marketing and management at Schering Plough Corporation. He joined Fisons plc in 1991 and became managing director of its pharmaceutical division, leaving after the company’s acquisition by Rhone Poulenc Rhorer in 1995.
Redmond’s appointment as Abcam’s non-executive deputy chairman is in preparation for David Cleevely, the company’s co-founder and chairman, to step down from the company’s board in due course. Cleevely, who co-founded Abcam in 1998 and has served on the company’s board for more than 10 years, is expected to leave the company by the end of this calendar year to pursue other business interests.
David Cleevely, Abcam’s chairman, said: “I am delighted to welcome Michael Redmond to Abcam’s Board in the role of deputy chairman. Michael’s breadth of experience in the healthcare industry will be of great value in the future development of Abcam. It is my intention, after more than ten years, to step down from the Company’s Board by the end of this calendar year, safe in the knowledge that Abcam is ideally positioned to achieve its goal of building the world’s largest online antibody resource.”